1.8.2010 - Reata to Present at J.P. Morgan Conference on 1/14 at 1:00 PST

Reata Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference Presentation Scheduled for January 14, 1:00 p.m. PST

IRVING, TX - January 8, 2010 -- Reata Pharmaceuticals, Inc. announces that J. Warren Huff, Chief Executive Officer and President, will present a company overview at the 28th Annual J.P. Morgan Healthcare Conference. The presentation will be held at 1:00 p.m. PST in the Elizabethan C/D Room at the Westin St. Francis Hotel in San Francisco, CA.

Mr. Huff's presentation will include an update on the clinical development of bardoxolone methyl, a first-in-class antioxidant inflammation modulator (AIM) for the treatment of advanced chronic kidney disease. Bardoxolone is currently in a pivotal clinical trial in diabetic patients, and 6-month estimated glomerular filtration rate results from this study are anticipated in the first half of 2010. Mr. Huff will also describe the company's recently-announced licensing, co-development and commercialization collaboration with Kyowa Hakko Kirin for bardoxolone in Japan, China and certain other Asian markets.
About Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases. Reata is the leader in discovering and developing novel anti-inflammatory drugs targeting Nrf2, which controls the body's production of antioxidant and detoxification enzymes and has been shown to protect against a broad range of diseases associated with inflammation and oxidative stress. Reata is developing a portfolio of antioxidant inflammation modulators (AIMs) for a variety of inflammation-related diseases. The company's most advanced program is in late-stage clinical development for the treatment of chronic kidney disease, a progressive condition affecting more than 26 million Americans. For more information, visit www.reatapharma.com.

Media Contact: Kathryn Morris (845) 635-9828 kathryn@proncall.com

Investor Contact: Alan Roemer (646) 378-2945 aroemer@troutgroup.com

Download PDF »